Perfume compositions – Perfume compositions – With preservative – stabilizer – or fixative
Reexamination Certificate
2006-06-13
2006-06-13
Yu, Misook (Department: 1642)
Perfume compositions
Perfume compositions
With preservative, stabilizer, or fixative
Reexamination Certificate
active
07060667
ABSTRACT:
Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 0 873 998 (1998-10-01), None
patent: WO 92/00329 (1992-01-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 96/01121 (1996-01-01), None
patent: WO 96/23071 (1996-08-01), None
patent: WO 97/03687 (1997-02-01), None
Hillion et al, Leukemia Mar. 1993;7(3):410-7.
Hagemeijer, Leukemia, 1992, vol. 6, Suppl. 4, pp. 16-18.
Higuchi et al (Biochem Biophys Res Commun. Jan. 31, 1992;182(2):638-43).
Qin et al ( 1995, Blood, vol. 85, 2779-85).
Reisfeld et al (Apr. 15, 1996, Cancer Res. vol. 56, pp. 1707-1712).
Wong et al (1996, Journal of Cellular Biochemistry, vol. 6-, pp. 56-60).
Alexopoulou et al., 1996, European Cytokine Network, 7:2:228, “Immunregulatory Activities of Transmembrane TNF Revealed in Transgenic and Mutant Mice”.
Androlewicz et al., 1992, J. of Biol. Chem., 267:4:2542-2547, “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein of the Surface of an Activated Human T Cell Hybridoma”.
Arulanandam et al., 1993, J. Exp. Med., 177:1439-1450, “A Soluble Multimeric Recombinant CD2 Protein . . . ”.
Banks et al., 1995, J. of Immunol., 155:1685-1693, “Lymphotoxin-α-Deficient Mice”.
Browning et al., 1991, 147:4:1230-1237, “Lymphotoxin and an Associated 3-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma”.
Browning et al., 1995, J. of Immunology, 154:33-46, “Characterization of Surface Lymphotoxin Forms . . . ”.
Browning et al., 1993, Cell, 72:847-856, “Lymphotoxin β, a Novel Member of the TNF Family . . . ”.
Crowe et al., 1994, Science, 264:707-710, “A Lymphotoxin-β-Specific Receptor”.
De Togni et al., 1994, Science, 264:703-708, “Abnormal Development of Peripheral Lymphoid Organs in Mice Deficient in Lympotoxin”.
Erickson et al., 1994, Nature, 372:560-563, “Decreased sensitivity to tumour-necrosis factor but normal T-Cell development . . . ”.
Ettinger et al., 1996, Proc. Natl. Acad. Sci., 93:13102-13107, “Disrupted splenic architecture, but normal lymph node development in mice . . . ”.
Ware et al., 1995, Pathways for Cytolysis, 175-218, “The Ligands and Receptors of the Lymphotoxin System”.
Katz et al., 1981, Cellular Immunol., 65:84-92, “Growth of SJL/J-Derived Transplantable Reticulum Cell Sarcoma as Related to Its Ability to Induce T-Cell Proliferation in the Host”.
Lane et al., 1992, Eur. J. Immunol., 22:2573-2578, “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T-Cell-dependent activation of B lymphocytes”.
Lasky et al., 1988, J. of Immunol., 14:2:679-687, “Characterization and Growth Factor Requirements of SJL Lymphomas . . . ”.
Lasky et al., 1989, Eur. J. Immunol., 19:365-371, “Characterization and growth factor requirements of SJL lympomas . . . ”.
Le Hir et al., 1996, J. Exp. Med., 183:2367-2372, “Differentiation of Follicular Dendritic Cells and Full Antibody . . . ”.
Mackay et al., 1997, Eur. J. Immunol., 27:2033-2042, “Lymphotoxin but not tumor necrosis factor functions to maintain splenic . . . ”.
Matsumoto et al., 1996, Nature, 382:462-466, “Affinity maturation without germinal centres in lymphotoxin-α-deficient mice”.
Matsumoto et al., 1997, J. Exp. Med., 186:12:1997-2004, “Distinct Roles of Lymphotoxin α and the Type 1 Tumor Necrosis Factor (TNF) Receptor in the Establishment of Follicular Dendritic Cells . . . ”.
Pasparakis et al., 1996, Eur. Cytokine Netw., 7:2:239, “Immune and Inflammatory Responses in TNFa Deficient Mice:A Critical Requirement . . . ”.
Matsumoto et al., 1996, Science, 271:1289-1291, “Role of Lymphotoxin and the Type I TNF Receptor in the Formation of Germinal Centers”.
Pfeffer et al., 1993, Cell, 73:457-467, “Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection”.
Picarella et al., 1992, Proc. Natl. Acad. Sci., 89:10036-10040, “Insulitis in transgenic mice expressing tumor necrosis factor β (lymphotoxin) in the pancreas”.
Picker et al., 1992, Annu. Rev. Immunol., 10:561-591, “Physiological and Molecular Mechanisms of Lymphocyte Homing”.
Ponzio et al., 1986, Inter. Rev. Immunol., 1:273-301, “Host-Tumor Interactions in the SJL Lymphoma Model”.
Queen et al., 1989, Proc. Natl Acad. Sci., 86:10029-10033, “A humanized antibody that binds to the interleukin 2 receptor”.
Rennert et al., 1996, J. Exp. Med., 184:1999-2006, “Surface Lymphotoxin α/β Complex Is Required for the Development of Peripheral Lymphoid Organs”.
Robert et al., 1998, Nature, 395:26-27, “Turning off follicular dendritic cells”.
Rothe et al., 1993, Nature, 364:798-802, “Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes”.
Selmaj et al., 1991, J. Clin Invest., 87:949-954, “Identification of Lymphotoxin and Tumor Necrosis Factor in Multiple Sclerosis Lesions”.
Traunecker et al., 1989, Nature, 339:68-70, “Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules”.
Tsiagbe et al., 1993, J. of Immunol., 150:12:5519-5528, “Syngeneic Response to SJL Follicular Center B Cell Lymphoma (Reticular Cell Sarcoma) Cells Is Primarily in Vβ16 CD4 T Cells ”.
Tsiagbe et al., 1996, Critical Reviews in Immunol., 16:381-421, “The Physiology of Germinal Centers”.
Winter et al., 1991, Nature, 349:293-299, “Man-made antibodies”.
Morrison, Sherie, L., 1992, Annu. Rev. Immunol., 10:239-265, “In Vitro Antibodies: Strategies for Production and Application”.
Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”.
Browning JL et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines, J Exp Med. Mar. 1, 1996; 183(3):867-78.
Rennert et al. Normal development of lymph nodes is disrupted by soluble LTα receptor—lg fusion protein. Eur. Cytokine Network, 1996 7:167.
Browning Jeffrey
Thorbecke Jeanette
Tsiagbe Vincent
Biogen Idec MA Inc.
Lahive & Cockfield
Mandragouras Amy E.
New York University
Yu Misook
LandOfFree
Treatment of follicular lymphomas using inhibitors of the LT... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of follicular lymphomas using inhibitors of the LT..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of follicular lymphomas using inhibitors of the LT... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649739